phentermine has been researched along with Blood Pressure, High in 10 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is a perception that phentermine pharmacotherapy for obesity increases blood pressure and heart rate (HR), exposing treated patients to increased cardiovascular risk." | 7.77 | Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. ( Greenway, FL; Gupta, AK; Hendricks, EJ; Westman, EC, 2011) |
| "In people with elevated blood pressure, orlistat, phentermine/topiramate and naltrexone/bupropion reduced body weight; the magnitude of the effect was greatest with phentermine/topiramate." | 5.12 | Long-term effects of weight-reducing drugs in people with hypertension. ( Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S, 2021) |
| "There is a perception that phentermine pharmacotherapy for obesity increases blood pressure and heart rate (HR), exposing treated patients to increased cardiovascular risk." | 3.77 | Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. ( Greenway, FL; Gupta, AK; Hendricks, EJ; Westman, EC, 2011) |
| "Nineteen participants, all of whom had hypertension, were being treated with fenfluramine or dexfenfluramine (5 on these agents alone, 14 also with phentermine)." | 3.71 | Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. ( Arnett, DK; Bella, JN; de Simone, G; Devereux, RB; Hopkins, PN; Kitzman, DW; Liu, JE; Morgan, D; Oberman, A; Palmieri, V; Roman, MJ, 2002) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| "Hypertension is a major risk factor for cardiovascular and renal diseases in the United States and worldwide." | 2.72 | Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. ( Ard, JD; Cohen, JB; Egan, BM; Hall, JE; Hall, ME; Lavie, CJ; Ma, J; Ndumele, CE; Schauer, PR; Shimbo, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, ME | 1 |
| Cohen, JB | 1 |
| Ard, JD | 1 |
| Egan, BM | 1 |
| Hall, JE | 1 |
| Lavie, CJ | 1 |
| Ma, J | 1 |
| Ndumele, CE | 1 |
| Schauer, PR | 1 |
| Shimbo, D | 1 |
| Siebenhofer, A | 2 |
| Winterholer, S | 1 |
| Jeitler, K | 2 |
| Horvath, K | 2 |
| Berghold, A | 2 |
| Krenn, C | 1 |
| Semlitsch, T | 2 |
| Chua, MWJ | 1 |
| Lai, BC | 1 |
| Posch, N | 1 |
| Meschik, J | 1 |
| Hendricks, EJ | 1 |
| Greenway, FL | 2 |
| Westman, EC | 1 |
| Gupta, AK | 1 |
| Stephens, LC | 1 |
| Katz, SG | 1 |
| Derby, LE | 1 |
| Myers, MW | 1 |
| Jick, H | 1 |
| Ryan, DH | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Palmieri, V | 1 |
| Arnett, DK | 1 |
| Roman, MJ | 1 |
| Liu, JE | 1 |
| Bella, JN | 1 |
| Oberman, A | 1 |
| Kitzman, DW | 1 |
| Hopkins, PN | 1 |
| Morgan, D | 1 |
| de Simone, G | 1 |
| Devereux, RB | 1 |
| Hoyer, I | 1 |
| Van Zwieten, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal[NCT01402674] | 269 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| [NCT00005267] | 3,604 participants (Actual) | Observational | 1995-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phentermine and Blood Pressure, High
| Article | Year |
|---|---|
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association.
Topics: American Heart Association; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Exercise; | 2021 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet | 2021 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Fema | 2016 |
7 other studies available for phentermine and Blood Pressure, High
| Article | Year |
|---|---|
Phentermine-Induced Acute Kidney Injury Secondary to Uncontrolled Hypertension in a Patient with Weight Regain Post-bariatric Surgery.
Topics: Acute Kidney Injury; Bariatric Surgery; Humans; Hypertension; Obesity, Morbid; Phentermine; Weight G | 2021 |
Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cohort Studies; Diet, Carbohydrate-Restricted; Diet, Ket | 2011 |
Phentermine and anaesthesia.
Topics: Alfentanil; Androstanols; Anesthesia; Anesthetics, Intravenous; Appetite Depressants; Blood Pressure | 2005 |
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke.
Topics: Aged; Appetite Depressants; Body Mass Index; Case-Control Studies; Cerebrovascular Disorders; Cohort | 1999 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.
Topics: Aortic Valve Insufficiency; Appetite Depressants; Dexfenfluramine; Drug Combinations; Female; Fenflu | 2002 |
The central hypotensive action of amphetamine, ephedrine, phentermine, chlorphentermine and fenfluramine.
Topics: Amphetamine; Animals; Appetite Depressants; Blood Pressure; Cats; Chlorphentermine; Depression, Chem | 1972 |